← Human Trials & Peer-Reviewed Studies
[Influence of recombinant human growth hormone on the prognosis of patients with severe burns a prospective multi-center clinical trial].
Plain-language guide to PMID 16383035 (2005): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 207 patients.
Key Facts
- PMID
- 16383035
- Journal
- Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Chen GX et al. (2 authors)
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).
To investigate the influence of recombinant human growth hormone (rhGH) on the mortality of the patients with severe burns.
Who Took Part
The abstract describes 207 patients taking part.
PubMed indexes the participants as teenagers, young adults, adults, middle-aged adults and older adults, both men and women.
In a prospective multi-center randomized clinical trial, 207 adult patients with severe burns were enrolled in the study, and they were randomly divided into treatment (T, with subcutaneous injection of rhGH) and placebo control (C, with subcutaneous injection of same amount of isotonic saline) groups.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Some patients received a placebo instead of Exogenous HGH, sermorelin & older GHRPs (why they're passed over), giving a reference point.
The mortality, incidence of hyperglycemia and sepsis in the two groups were observed.
What Was Measured
PubMed files the paper under topics including Blood Glucose, Burns, Human Growth Hormone and Prognosis.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 207 patients.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2005 (Zhonghua shao shang za zhi = Zhonghua shaoshang zazhi = Chinese journal of burns), a journal based in China.
More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.
Our Notes on the Compound
Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.